Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:6
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Antiepileptic medication use in a population-based cohort of adults with intellectual disability and epilepsy
    Deb, S
    Joyce, J
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2000, 44 : 260 - 260
  • [22] Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature
    Deb, Shoumitro
    Unwin, Gemma L.
    CURRENT OPINION IN PSYCHIATRY, 2007, 20 (05) : 461 - 466
  • [23] Longitudinal psychotropic medication patterns among former residents with intellectual disability in Ontario
    Hansford, Rebecca
    Condillac, Rosemary
    JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2021, 34 (05) : 1318 - 1318
  • [24] Prevalence and Determinants of Psychotropic Drug Use in Institutionalized Children and Adolescents with Mild Intellectual Disability and Behavioural Problems
    Scheifes, Arlette
    de Jong, Daniel
    Stolker, Joost Jan
    Nijman, Henk L. I.
    Egberts, Antoine C. G.
    Heerdink, Eibert R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 138 - 138
  • [25] Psychotropic Medication Use in Children and Adolescents With Down Syndrome
    Downes, Alison
    Anixt, Julia S.
    Esbensen, Anna J.
    Wiley, Susan
    Meinzen-Derr, Jareen
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2015, 36 (08): : 613 - 619
  • [26] Audit on use of PRN (pro re nata) psychotropic medication for behavioural disturbance in individuals with intellectual disability in the community
    Dhandapani, Asha
    Soundararajan, Sathyan
    Jones, Claire
    BJPSYCH OPEN, 2021, 7 : S75 - S76
  • [27] Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK
    Sheehan, Rory
    Hassiotis, Angela
    Strydom, Andre
    Morant, Nicola
    BMJ OPEN, 2019, 9 (11):
  • [28] Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents
    Walkup, John
    Bernet, William
    Bukstein, Oscar
    Walter, Heather
    Arnold, Valerie
    Benson, Scott
    Beitchnian, Joseph
    Chrisman, Allan
    Farchione, Tiffany R.
    Hamilton, John
    Keable, Helene
    Kinlan, Joan
    McClellan, Jon
    Schoettle, Ulrich
    Shaw, Jon
    Siegel, Matthew
    Stock, Saundra
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (09): : 961 - 973
  • [29] Psychotropic Medication Use in Children and Adolescents With Down Syndrome
    Downes, Alison
    Anixt, Julia
    Esbensen, Anna
    Meinzen-Derr, Jareen
    Wiley, Susan
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2015, 36 (02): : S10 - S11
  • [30] Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study
    Bowring, D. L.
    Totsika, V.
    Hastings, R. P.
    Toogood, S.
    McMahon, M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2017, 61 (06) : 604 - 617